MA32891B1 - Derives de pyridine et de pyrimidine comme inhibiteurs de phosphodiesterase 10 - Google Patents

Derives de pyridine et de pyrimidine comme inhibiteurs de phosphodiesterase 10

Info

Publication number
MA32891B1
MA32891B1 MA33931A MA33931A MA32891B1 MA 32891 B1 MA32891 B1 MA 32891B1 MA 33931 A MA33931 A MA 33931A MA 33931 A MA33931 A MA 33931A MA 32891 B1 MA32891 B1 MA 32891B1
Authority
MA
Morocco
Prior art keywords
pyridine
pyrimidine derivatives
phosphodiesterase inhibitors
compulsive
compounds
Prior art date
Application number
MA33931A
Other languages
Arabic (ar)
English (en)
Inventor
Jennifer R Allen
Kaustav Biswas
Frank Chavez Jr
Ning Chen
Frenel Fils Demorin
James R Falsey
Mike Frohn
Paul Harrington
Daniel B Horne
Essa Hu
Matthew R Kaller
Roxanne Kunz
Holger Monenschein
Tom Nguyen
Alex Pickrell
Andreas Reichelt
Shannon Rumfelt
Rob Rzasa
Kelvin Sham
Guomin Yao
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA32891B1 publication Critical patent/MA32891B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

L'invention concerne des composés de pyridine et de pyrimidine, des compositions les contenant, et des processus de préparation de ces composés. L'invention concerne en outre des procédés permettant de traiter des troubles ou des maladies que l'on peut traiter par inhibition de PDE10, par exemple l'obésité, les diabètes non insulino-dépendants, la schizophrénie, le trouble bipolaire, le trouble obsessionnel compulsif, etc.
MA33931A 2008-11-14 2011-06-10 Derives de pyridine et de pyrimidine comme inhibiteurs de phosphodiesterase 10 MA32891B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11459508P 2008-11-14 2008-11-14
US16621509P 2009-04-02 2009-04-02
PCT/US2009/064643 WO2010057126A1 (fr) 2008-11-14 2009-11-16 Derives de pyridine et de pyrimidine comme inhibiteurs de phosphodiesterase 10

Publications (1)

Publication Number Publication Date
MA32891B1 true MA32891B1 (fr) 2011-12-01

Family

ID=41557471

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33931A MA32891B1 (fr) 2008-11-14 2011-06-10 Derives de pyridine et de pyrimidine comme inhibiteurs de phosphodiesterase 10

Country Status (17)

Country Link
US (2) US8318718B2 (fr)
EP (1) EP2364306B1 (fr)
JP (1) JP2012508777A (fr)
KR (1) KR20110086603A (fr)
AR (1) AR074343A1 (fr)
AU (1) AU2009313773B2 (fr)
BR (1) BRPI0921598A2 (fr)
CA (1) CA2742833C (fr)
CR (1) CR20110279A (fr)
EA (1) EA201100749A1 (fr)
ES (1) ES2413808T3 (fr)
IL (1) IL212670A0 (fr)
MA (1) MA32891B1 (fr)
MX (1) MX2011005093A (fr)
TN (1) TN2011000220A1 (fr)
TW (1) TW201030001A (fr)
WO (1) WO2010057126A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927549B2 (en) 2008-11-21 2015-01-06 High Point Pharmaceuticals, Llc Adamantyl benzamide derivatives
AU2010211050B2 (en) 2009-02-05 2016-05-12 Takeda Pharmaceutical Company Limited Pyridazinone compounds
WO2011163355A1 (fr) 2010-06-24 2011-12-29 Takeda Pharmaceutical Company Limited Composés hétérocycliques condensés comme inhibiteurs de phosphodiestérases (pdes)
US9029536B2 (en) 2010-08-04 2015-05-12 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
EP2602255B1 (fr) 2010-08-04 2017-04-26 Takeda Pharmaceutical Company Limited Composé à cycle hétérocyclique fusionné
US9150588B2 (en) 2010-08-10 2015-10-06 Takeda Pharmaceutical Company Limited Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors
US8765760B2 (en) 2011-01-11 2014-07-01 Sunovion Pharmaceuticals, Inc. [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases
CA2827724A1 (fr) 2011-02-18 2012-08-23 Allergan, Inc. Derives de 6,7-dialkoxy-3-isoquinolinol substitues en tant qu'inhibiteurs de la phosphodiesterase 10 (pde10a)
WO2012124782A1 (fr) 2011-03-16 2012-09-20 武田薬品工業株式会社 Composé hétérocyclique condensé
MX354412B (es) 2011-06-10 2018-03-05 Merck Patent Gmbh Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton.
TWI570122B (zh) 2011-06-22 2017-02-11 武田藥品工業股份有限公司 稠合雜環化合物之結晶
EP2723718A1 (fr) 2011-06-24 2014-04-30 Amgen Inc. Antagonistes de trpm8 et leur utilisation dans le cadre thérapeutique
JP2014527511A (ja) 2011-06-24 2014-10-16 アムジエン・インコーポレーテツド Ｔｒｐｍ８拮抗剤及び治療におけるそれらの使用
BR112014004310B8 (pt) * 2011-08-25 2023-04-18 Merck Sharp & Dohme Composto de pirimidina inibidor da enzima fosfodiesterase 10, composição farmacêutica, uso de um composto
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
WO2014071044A1 (fr) 2012-11-01 2014-05-08 Allergan, Inc. Dérivés de 6,7-dialcoxy-3-isoquinoline substitués à titre d'inhibiteurs de phosphodiestérase 10 (pde10a)
US9464076B2 (en) 2013-03-15 2016-10-11 Daiichi Sankyo Company, Limited Benzothiophene derivative
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
CN106232122A (zh) 2013-09-27 2016-12-14 林伯士艾瑞斯公司 Irak抑制剂和其用途
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
KR102494596B1 (ko) * 2014-07-31 2023-01-31 재단법인 한국파스퇴르연구소 2-아미노-벤즈이미다졸 유도체 및 5-리폭시게나아제 및/또는 프로스타글란딘 e 합성효소 억제제로서의 이들의 용도
SG11201801856XA (en) 2015-09-18 2018-04-27 Kaken Pharmaceutical Co Ltd Biaryl derivative and medicine containing same
CN110563664A (zh) * 2019-07-23 2019-12-13 上海合全药物研发有限公司 外消旋体(4as,7s,7as)-叔丁基-7-羟基六氢环戊二烯[b][1,4]噁嗪-4(4ah)-甲酸基酯制法
CN119119063A (zh) 2021-05-12 2024-12-13 勃林格殷格翰国际有限公司 作为cGAS抑制剂的具有N-连接环状取代基的吡啶衍生物
WO2022238335A1 (fr) * 2021-05-12 2022-11-17 Boehringer Ingelheim International Gmbh Dérivés de pyridine ayant des substituants cycliques liés à c en tant qu'inhibiteurs de cgas
KR102840252B1 (ko) * 2023-04-27 2025-07-30 한국화학연구원 시아노벤즈이미다졸 유도체, 약제학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198417A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
US7064215B2 (en) * 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
NZ540891A (en) 2003-04-04 2008-07-31 Lundbeck & Co As H 4-(2-Phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
DE10337942A1 (de) 2003-08-18 2005-03-17 Merck Patent Gmbh Aminobenzimidazolderivate
DE10344223A1 (de) * 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
DE10349587A1 (de) * 2003-10-24 2005-05-25 Merck Patent Gmbh Benzimidazolylderivate
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
DE102005016634A1 (de) 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
CN101273023A (zh) 2005-08-02 2008-09-24 Irm责任有限公司 作为蛋白激酶抑制剂的5-取代的噻唑-2-基氨基化合物和组合物
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
US7868177B2 (en) 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
WO2008057280A1 (fr) 2006-10-27 2008-05-15 Amgen Inc. Composés à cycles multiples et procédés d'utilisation
WO2009081259A1 (fr) 2007-12-21 2009-07-02 Pfizer Inc. Dérivés phénoxy-pyridylés
CA2727174A1 (fr) 2008-06-20 2010-01-21 Jiangao Song Agonistes des recepteurs gpr119 aryles et utilisations associees

Also Published As

Publication number Publication date
MX2011005093A (es) 2011-09-27
EP2364306B1 (fr) 2013-04-24
TN2011000220A1 (en) 2012-12-17
KR20110086603A (ko) 2011-07-28
CA2742833A1 (fr) 2010-05-20
US20130079325A1 (en) 2013-03-28
TW201030001A (en) 2010-08-16
BRPI0921598A2 (pt) 2016-02-10
US8318718B2 (en) 2012-11-27
AU2009313773A1 (en) 2010-05-20
AU2009313773B2 (en) 2013-03-21
EP2364306A1 (fr) 2011-09-14
EA201100749A1 (ru) 2011-10-31
ES2413808T3 (es) 2013-07-17
JP2012508777A (ja) 2012-04-12
WO2010057126A1 (fr) 2010-05-20
CA2742833C (fr) 2013-12-31
IL212670A0 (en) 2011-07-31
US20100125062A1 (en) 2010-05-20
CR20110279A (es) 2011-09-22
US8759532B2 (en) 2014-06-24
AR074343A1 (es) 2011-01-12

Similar Documents

Publication Publication Date Title
MA32891B1 (fr) Derives de pyridine et de pyrimidine comme inhibiteurs de phosphodiesterase 10
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MX2008011258A (es) Derivados de quinazolina como inhibidores de fosfodiesterasa 10.
TN2011000221A1 (en) Pyrazine compounds as phosphodiesterase 10 inhibitors
MX2008010953A (es) Derivados de cinolina y quinoxalina como inhibidores de la fosfodiesterasa 10.
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
WO2006105516A3 (fr) Compositions et procedes pour le diagnostic et le traitement de troubles neuropsychiatriques
MX2009008099A (es) Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
MX2009006630A (es) Derivados de 4-imidazolil-1,2,3,4-tetrahidro-quinola y su uso como inhibidores de aldosterona / 11-beta-hidroxilasa.
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
MA29140B1 (fr) Dérivés de quinoléine hétéroaromatiques et leur utilisation comme inhibiteurs de PDE10
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MX2009006170A (es) Compuestos y composiciones como inhibidores de cinasa.
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
WO2006009836A3 (fr) Composes associes au facteur de differenciation tissulaire et leurs analogues
MX2012004548A (es) Nuevas composiciones para prevenir y/o tratar transtornos degenerativos del sistema nervioso central.
WO2009038842A3 (fr) Procédés et compositions pour inhiber le facteur d'œdème et l'adénylylcyclase
ATE553093T1 (de) Indazolderivate zur hemmung von trpv1 und verwendungen davon
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
TW200745059A (en) Sulfonyl-substituted bicyclic compounds as modulators of PPAR
WO2007035872A3 (fr) Composés apparentés au fdt et leurs analogues
MA37748A1 (fr) Composés d'azétidine et de pipéridine utiles comme inhibiteurs de pde10
WO2007013936A3 (fr) Methode de traitement de troubles et d'affections du systeme nerveux